Verrica Pharmaceuticals Announces Acceptance by FDA of NDA Resubmission for VP-102

Verrica Pharmaceuticals Inc

WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that the U.S. Food and Drug Administration (FDA) recently acknowledged that Verrica’s resubmitted New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum) was complete and assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2022.

“We are pleased that the FDA has accepted our NDA resubmission for VP-102,” said Ted White, Verrica’s President and Chief Executive Officer. “While we recognize the demands of the Agency’s current workload, we intend to work with the FDA toward approval as quickly as possible based on the limited changes in our resubmission.

“We continue to be encouraged by the overwhelming demand from both caregivers and the medical community for an FDA-approved treatment for molluscum, one of the largest unmet needs in medical dermatology.”

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.

Thanks for visiting! Looking for some Chester County pride? We got you covered! Shop our MyChesCo store and show your love for Chester County, Pennsylvania. We got shirts, hats, and more – all with a unique ChesCo flair. Plus, proceeds from each purchase helps support our mission of bringing reliable information and resources to the people of Chester County.